Applied DNA Sciences develops and markets DNA-based technology solutions utilizing its LinearDNA polymerase chain reaction (PCR) based manufacturing platform. Co.'s proprietary platform produces DNA for use in nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing market and for supply chain security, anti-counterfeiting and anti-theft technology purposes. In addition, Co. has developed a PCR-based molecular diagnostic test for SARS-CoV-2 (COVID-19). Co. manufactures and sells its Emergency Use Authorization authorized COVID-19 molecular diagnostic test kit under the Linea COVID-19 Assay Kit. We show 37 historical shares outstanding datapoints in our coverage of APDN's shares outstanding history.
Understanding the changing numbers of APDN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like APDN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching APDN by allowing them to research APDN shares outstanding history
as well as any other stock in our coverage universe. |